TITLE:
EVA: Evista Alendronate Comparison

CONDITION:
Osteoporosis

INTERVENTION:
raloxifene HCI and alendronate Na

SUMMARY:

      The purpose of this study is to determine how treatment with raloxifene compares to
      treatment with alendronate in postmenopausal women with osteoporosis on the chance of
      experiencing fractures
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 50 Years to 80 Years
Criteria:

        Inclusion Criteria

          -  50-80 years of age, inclusive

          -  2 years since last menses

          -  Dx femoral neck osteoporosis

          -  No vertebral fractures

        Exclusion Criteria

          -  Poor candidate for study drugs

          -  Hx of diseases affecting bone metabolism

          -  Hx of breast/estrogen-dependent cancer

          -  Current use of osteoporosis drug therapy

          -  Hx/high risk of VTE
      
